MSB — Mesoblast Income Statement
0.000.00%
Last trade - 00:00- AU$2.06bn
- AU$2.20bn
- $5.90m
- 43
- 19
- 95
- 54
Annual income statement for Mesoblast, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 32.2 | 7.46 | 10.2 | 7.5 | 5.9 |
| Cost of Revenue | |||||
| Gross Profit | 6.85 | -25.3 | -20.5 | -20.2 | -9.81 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 105 | 92.6 | 84.4 | 70.9 | 75.1 |
| Operating Profit | -72.9 | -85.2 | -74.1 | -63.4 | -69.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -87.4 | -99.6 | -91.6 | -82.1 | -88.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -77.9 | -98.8 | -91.3 | -81.9 | -88 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -77.9 | -98.8 | -91.3 | -81.9 | -88 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -77.9 | -98.8 | -91.3 | -81.9 | -88 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.14 | -0.16 | -0.133 | -0.105 | -0.088 |